reports
- ABGSC Healthcare Research
- Alexander Krämer
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provid...
Ultimovacs ASA Reports Third Quarter 2024 Financial Results and Provides General Business Update Oslo, November 6, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its third quarter 2024 results today. Conference call and webcast scheduled for November 6, 2024, at 14:00 (CET). Link to webcast . Third Quarter 2024 Business Update Highlights Ultimovacs implemented cash preservation initiatives during the second quarter of 2024. During the third quarter of 2024, additional cash preservation op...
Ultimovacs ASA: Invitation to third quarter 2024 results webcast prese...
Ultimovacs ASA: Invitation to third quarter 2024 results webcast presentation Oslo, October 31, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its third quarter 2024 results, on Wednesday, November 6, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Wednesday, November 6, 2024. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation throug...
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on me...
Ultimovacs Announces Publication of Phase II FOCUS Trial Results on medRxiv Oslo, October 25, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the results from Phase II FOCUS trial () have been on the preprint platform medRxiv. As previously , topline data readout demonstrated that adding UV1 to the standard of care pembrolizumab did not lead to clinical benefits in progression free survival or overall survival in the late-stage head and neck squamous cell carcinoma (HNSCC) patients recruited in th...
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Tr...
Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Oslo, September 11, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial () to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab o...
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial ...
Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 Oslo, September 9, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II NIPU trial (), at the . The NIPU trial evaluated the addition of UV1 telomerase vaccine to immunotherapy with ipilimumab and nivolumab compared with ipilimumab and nivolumab alone, as a second-line treatment for patients with inoperable malignant pleural mesothelioma. As at ESMO 20...
- Geir Hiller Holom
Ultimovacs (Sell, TP: NOK2.50) - Slow recruitment continues
We remain concerned about Ultimovacs’s ability to generate significant investor interest ahead of the next financing round, and note that recruitment continues to slow. We have made minor estimate revisions, and see further downside risk on the DOVACC and LUNGVAC trials being fully recruited as guided. We reiterate our SELL and have cut our target price to NOK3 (4).
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provi...
Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its second quarter 2024 results today. Conference call and webcast scheduled for August 21, 2024, at 14:00 (CET). Link to webcast . Second Quarter 2024 Business Update Following the negative INITIUM result in March 2024, Ultimovacs implemented cash preservation initiatives during the second quarter of 2024 extending...
Ultimovacs ASA: Invitation to second quarter 2024 results webcast pres...
Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second quarter 2024 results on Wednesday, August 21, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Wednesday, August 21, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post...
Ultimovacs Announces Notice of Resignation from Deputy Board Member
Ultimovacs Announces Notice of Resignation from Deputy Board Member Oslo, August 7, 2024: (“Ultimovacs”) (OSE ULTI) today announced that it has received notice from deputy board member Ketil Fjerdingen that he has resigned from his position as deputy member of the Company’s Board of Directors. The Company wishes to thank Ketil Fjerdingen for his service to the Company over the years. For further information, please see or contact: Jónas Einarsson, Chair of the Board of Directors of Ultimovacs ASAEmail: Phone: 355
- Geir Hiller Holom
Ultimovacs (Sell, TP: NOK4.00) - Top-line results for FOCUS trial
Ultimovacs announced top-line results for the FOCUS trial (metastatic or recurrent head and neck cancer). While the results did not include detailed data, it was clear that the trial – as we expected – did not meet the primary and secondary endpoints. The failed study is another dramatic setback for the company, in our view, further denting our confidence in a clinical benefit of the UV1 vaccine across cancer indications. We remain concerned about Ultimovacs’ ability to generate investor interes...
- ABGSC Healthcare Research
- Alexander Krämer
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Com...
Ultimovacs Announces Topline Data from FOCUS Phase II Trial of UV1 Combined with Pembrolizumab in Patients with Metastatic or Recurrent Head and Neck Cancer Adding Ultimovacs’ cancer vaccine UV1 to checkpoint inhibitor pembrolizumab did not meet primary or secondary endpoints in patients with metastatic or recurrent head and neck squamous cell carcinomaUV1 continues to show a positive safety profile in line with other UV1 studies with similar events observed in the control arm and good tolerabilityAs previously communicated, financial runway secured until Q4 2025 beyond expected topline res...
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update...
Ultimovacs Announces Poster Presentation of NIPU Phase II Trial Update at Upcoming ESMO Congress 2024 Oslo, August 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that an update from the Phase II NIPU trial () in patients with malignant mesothelioma will be presented in a poster presentation at the 2024 ESMO Congress. The conference will be held in Barcelona, Spain from September 13-17, 2024. Poster Presentation Details: Title: Updated survival and vaccine response from the NIP...
- Sean Conroy
Ultimovacs - Termination of coverage
Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Ultimovacs ASA announces revised terms of the employee share option pr...
Ultimovacs ASA announces revised terms of the employee share option program Oslo, June 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, announces revised terms of the employee share option program. Ultimovacs has during the second quarter of this year implemented a cash preservation program that includes downsizing of the organization. As a measure to stimulate retention of non-redundant team members, the board of directors of Ultimovacs ASA has decided to revise the terms of parts of the share option p...
Ultimovacs provides update from Phase I study in malignant melanoma: C...
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab All patients in the trial who were alive at 3 years remain alive at 4 years (69.5%) with a minimum follow-up period of 4 years (median 53.0 months)The expected next key milestone for UV1 is the readout of the FOCUS trial during Q3 2024, in which the treatment combination is the same as in the UV1-103 trial Oslo, June 11, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company develo...
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website: /abstracts-presentations/232936...
- Geir Hiller Holom
Ultimovacs (Sell, TP: NOK4.00) - Slower recruitment, FOCUS in focus
Total operating expenses were NOK28.6m, and cash and cash equivalents were NOK220m at end-Q1 (NOK266.6m at end-Q4 2023). The company recently announced initiatives to extend the financial runway to Q4 2025. While data from the fully recruited FOCUS trial is expected in Q3, the number of new recruited patients in the DOVACC and LUNGVAC trials was lower in Q1 versus Q4 2023. We reiterate our SELL and NOK4 target price.
- ABGSC Healthcare Research
- Alexander Krämer
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.